{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:42:25Z","timestamp":1789764145102,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s11940-006-0013-y","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T20:17:51Z","timestamp":1181074671000},"page":"224-235","source":"Crossref","is-referenced-by-count":13,"title":["Initial treatment of parkinson\u2019s disease"],"prefix":"10.1007","volume":"8","author":[{"given":"Daniel","family":"Tarsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"Suppl 5","key":"13_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","volume":"56","author":"CW Olanow","year":"2001","unstructured":"Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson\u2019s disease (2001): treatment guidelines. Neurology 2001, 56(Suppl 5):S1-S88. A comprehensive, high-quality guide to treatment of early and more advanced PD.","journal-title":"Neurology"},{"key":"13_CR2","first-page":"569","volume-title":"Parkinson\u2019s Disease","author":"D Tarsy","year":"2005","unstructured":"Tarsy D: Diagnostic criteria for Parkinson\u2019s disease. In Parkinson\u2019s Disease. Edited by Ebadi M, Pfeiffer R. Boca Raton, FL: CRC Press; 2005:569\u2013578."},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181\u2013184.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861\u2013870.","journal-title":"Brain"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Schults","year":"2002","unstructured":"Schults CW, Oakes D, Kieburtz K, et al.: Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol 2002, 59:1541\u20131550.","journal-title":"Arch Neurol"},{"issue":"Suppl 4","key":"13_CR6","first-page":"S156","volume":"17","author":"CG Goetz","year":"2002","unstructured":"Goetz CG, Koller WC, Poewe W, et al.: Management of Parkinson\u2019s disease: an evidence-based review. Mov Disord 2002, 17(Suppl 4):S156-S159. This is an authoritative, evidence-based review of all treatment modalities used in PD.","journal-title":"Mov Disord"},{"key":"13_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.apmr.2004.08.008","volume":"86","author":"T Ellis","year":"2005","unstructured":"Ellis T, de Goede CJ, Feldman RG, et al.: Efficacy of a physical therapy program in patients with Parkinson\u2019s disease: a randomized controlled trial. Arch Phys Med Rehabil 2005, 86:626\u2013632.","journal-title":"Arch Phys Med Rehabil"},{"key":"13_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/mds.10259","volume":"17","author":"PC Rubinstein","year":"2002","unstructured":"Rubinstein PC, Giladi N, Hausdorff JM: The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson\u2019s disease. Mov Disord 2002, 17:1148\u20131160.","journal-title":"Mov Disord"},{"key":"13_CR9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/mds.20503","volume":"20","author":"A Cristian","year":"2005","unstructured":"Cristian A, Katz M, Cutrone E, Walker RH: Evaluation of acupuncture in the treatment of Parkinson\u2019s disease: a double-blind pilot study. Mov Disord 2005, 20:1185\u20131188.","journal-title":"Mov Disord"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.47.6.1496","volume":"47","author":"LO Ramig","year":"1996","unstructured":"Ramig LO, Countryman S, O\u2019Brien C, et al.: Intensive speech treatment for patients with Parkinson\u2019s disease: short- and long-term comparison of two techniques. Neurology 1996, 47:1496\u20131504.","journal-title":"Neurology"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","volume":"60","author":"BM Ravina","year":"2003","unstructured":"Ravina BM, Fagan SE, Hart RG, et al.: Neuroprotective agents for clinical trials in Parkinson\u2019s disease. Neurology 2003, 60:1234\u20131240.","journal-title":"Neurology"},{"key":"13_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jama.291.3.358","volume":"291","author":"AHV Schapira","year":"2004","unstructured":"Schapira AHV, Olanow CW: Neuroprotection in Parkinson disease. Mysteries, myths, and misconceptions. JAMA 2004, 291:358\u2013364. A useful overview of the methodologic problems of assessing potential neuroprotective agents.","journal-title":"JAMA"},{"key":"13_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","volume":"329","author":"NJ Ives","year":"2004","unstructured":"Ives NJ, Stowe RL, Marro J, et al.: Monoamine oxidase type B inhibitors in early Parkinson\u2019s disease: metaanalysis of 17 randomized trials involving 3,525 patients. BMJ 2004, 329:593\u2013596.","journal-title":"BMJ"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S031716710004124X","volume":"21","author":"CH Waters","year":"1994","unstructured":"Waters CH: Fluoxetine and selegiline--lack of significant interaction. Can J Neurol Sci 1994, 21:259\u2013261.","journal-title":"Can J Neurol Sci"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/106002809402800324","volume":"28","author":"SC Toyana","year":"1994","unstructured":"Toyana SC, Iacono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?\n                           Ann Pharmacother 1994, 28:405.","journal-title":"Ann Pharmacother"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","volume":"48","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R, Tanner C, et al.: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Neurology 1997, 48:1070\u20131077.","journal-title":"Neurology"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/bmj.317.7153.252","volume":"317","author":"M Thorogood","year":"1998","unstructured":"Thorogood M, Armstrong B, Nichols T, Hollowell J: Mortality in people taking selegiline: observational study. BMJ 1998, 317:252\u2013254.","journal-title":"BMJ"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/01.WNL.0000148603.44618.19","volume":"64","author":"C Marras","year":"2005","unstructured":"Marras C, McDermott NP, Rochon PA, et al.: Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohorts. Neurology 2005, 64:87\u201393.","journal-title":"Neurology"},{"key":"13_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"B Luginger","year":"2000","unstructured":"Luginger B, Wenning TK, Bosch S, Poewe W: Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 2000, 15:873\u2013878.","journal-title":"Mov Disord"},{"key":"13_CR20","doi-asserted-by":"crossref","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A: Anticholinergics for symptomatic management of Parkinson\u2019s disease. Cochrane Database Syst Rev 2003, CD003735.","DOI":"10.1002\/14651858.CD003735"},{"key":"13_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who have been treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484\u20131491.","journal-title":"N Engl J Med"},{"key":"13_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, et al.: Pramipexole vs levodopa as initial treatment for Parkinson disease: a four-year randomized controlled trial. Arch Neurol 2004, 61:1044\u20131053.","journal-title":"Arch Neurol"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","volume":"52","author":"S Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE, et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908\u20131910.","journal-title":"Neurology"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","volume":"61","author":"E Driver-Dunckley","year":"2003","unstructured":"Driver-Dunckley E, Samanth A, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease. Neurology 2003, 61:422\u2013423.","journal-title":"Neurology"},{"key":"13_CR25","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.4065\/77.12.1280","volume":"77","author":"AM Pritchett","year":"2002","unstructured":"Pritchett AM, Morrison JF, Edwards W, et al.: Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002, 77:1280\u20131286.","journal-title":"Mayo Clin Proc"},{"key":"13_CR26","first-page":"12","volume":"47","author":"Parcopa","year":"2005","unstructured":"Parcopa: A rapidly dissolving formulation of carbidopa\/ levodopa. Med Lett Drug Ther 2005, 47:12.","journal-title":"Med Lett Drug Ther"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","volume":"53","author":"WC Koller","year":"1999","unstructured":"Koller WC, Hutton JT, Tolosa E, et al.: Immediate-relief and controlled-relief carbidopa\/levodopa in Parkinson\u2019s disease. A five-year randomized multicenter study. Neurology 1999, 53:1012\u20131019.","journal-title":"Neurology"},{"key":"13_CR28","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Ann Neurol 1996, 39:37\u201345.","DOI":"10.1002\/ana.410390107"},{"issue":"Suppl 3","key":"13_CR29","first-page":"32","volume":"40","author":"CW Olanow","year":"1990","unstructured":"Olanow CW: Oxidation reactions in Parkinson\u2019s disease. Neurology 1990, 40(Suppl 3):32\u201337.","journal-title":"Neurology"},{"key":"13_CR30","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1001\/archneur.61.12.1966","volume":"61","author":"WJ Weiner","year":"2004","unstructured":"Weiner WJ: Initial treatment of Parkinson disease. Levodopa or dopamine agonist. Arch Neurol 2004, 61:1966\u20131969.","journal-title":"Arch Neurol"},{"key":"13_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0140-6736(05)70285-3","volume":"351","author":"Y Agid","year":"1998","unstructured":"Agid Y, Chase T, Marsden CD: Adverse reactions to levodopa: drug toxicity or progression of disease?\n                           Lancet 1998, 351:851\u2013852.","journal-title":"Lancet"},{"key":"13_CR32","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"The Parkinson Study Group","year":"2004","unstructured":"The Parkinson Study Group: Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 2004, 351:2498\u20132508.","journal-title":"N Engl J Med"},{"key":"13_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/mds.20243","volume":"19","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Agid Y, Mizuno Y, et al.: Levodopa in Parkinson\u2019s disease: Current controversies. Mov Disord 2004, 19:997\u20131005.","journal-title":"Mov Disord"},{"key":"13_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000064759","volume":"58","author":"J Miyasaki","year":"2002","unstructured":"Miyasaki J, Martin W, Suchowersky O, et al.: Practice parameter: initiation of treatment for Parkinson\u2019s disease: an evidence-based review. Neurology 2002, 58:11\u201317.","journal-title":"Neurology"},{"key":"13_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(05)79311-9","volume":"51","author":"JG Nutt","year":"1998","unstructured":"Nutt JG: Catechol-O-methyltransferase inhibitors for treatment of Parkinson\u2019s disease. Lancet 1998, 51:1221\u20131222.","journal-title":"Lancet"},{"key":"13_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","volume":"61","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Kieburtz K, Stern M, et al.: Double-blind, placebo-controlled study of entacapone in levodopatreated patients with stable Parkinson disease. Arch Neurol 2004, 61:1563\u20131568.","journal-title":"Arch Neurol"},{"key":"13_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/archneur.57.2.263","volume":"57","author":"CW Olanow","year":"2000","unstructured":"Olanow CW, Tasmar Advisory Panel: Tolcapone and hepatotoxic effects. Arch Neurol 2000, 57:263\u2013267. A thorough and realistic appraisal of the actual risk associated with use of tolcapone.","journal-title":"Arch Neurol"},{"key":"13_CR38","doi-asserted-by":"crossref","DOI":"10.1385\/1592598595","volume-title":"Parkinson\u2019s Disease and Nonmotor Dysfunction","author":"RF Pfeiffer","year":"2005","unstructured":"Pfeiffer RF, Botis-Wollmer I: Parkinson\u2019s Disease and Nonmotor Dysfunction. Totowa, NJ: Humana Press; 2005. A comprehensive reference dedicated to the relatively neglected area of non-motor aspects of PD."},{"key":"13_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.287.4.455","volume":"287","author":"DE Hobson","year":"2002","unstructured":"Hobson DE, Lang AE, Martin WRL: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455\u2013463.","journal-title":"JAMA"},{"key":"13_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archneur.61.1.97","volume":"61","author":"A Razmy","year":"2004","unstructured":"Razmy A, Lang AE, Shapiro CN: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004, 61:97\u2013102.","journal-title":"Arch Neurol"},{"key":"13_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00002826-200107000-00005","volume":"24","author":"G Dell\u2019Agnello","year":"2001","unstructured":"Dell\u2019Agnello G, Ceravello R, Nuti A, et al.: SSRIs do not worsen Parkinson\u2019s disease: evidence from an openlabel, prospective study. Clin Neuropharmacol 2001, 24:221\u2013227.","journal-title":"Clin Neuropharmacol"},{"key":"13_CR42","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease. Arch Neurol 2002, 59:1937\u20131943.","journal-title":"Arch Neurol"},{"key":"13_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson\u2019s disease and motor fluctuations. Arch Neurol 2005, 62:241\u2013248.","journal-title":"Arch Neurol"},{"key":"13_CR44","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","volume":"62","author":"Parkinson Study Group","year":"2003","unstructured":"Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson\u2019s disease. Arch Neurol 2003, 62:1721\u20131728.","journal-title":"Arch Neurol"},{"key":"13_CR45","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mds.20036","volume":"19","author":"CH Waters","year":"2004","unstructured":"Waters CH, Sethi KD, Hauser RA, et al.: Zydis selegiline reduces off time in Parkinson\u2019s disease patients with motor fluctuations: a three-month, randomized, placebo-controlled study. Mov Disord 2004, 19:426\u2013432.","journal-title":"Mov Disord"},{"key":"13_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ana.20361","volume":"57","author":"JJ Elm","year":"2005","unstructured":"Elm JJ, Goetz CG, Ravina B, et al.: A responsive outcome for Parkinson\u2019s disease neuroprotection futility studies. Ann Neurol 2005, 57:197\u2013203.","journal-title":"Ann Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-006-0013-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0013-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:29:41Z","timestamp":1652614181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-006-0013-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s11940-006-0013-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}